These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 25534238)

  • 41. Primary glioblastoma multiforme tumors and recurrence : Comparative analysis of the danger signals HMGB1, HSP70, and calreticulin.
    Muth C; Rubner Y; Semrau S; Rühle PF; Frey B; Strnad A; Buslei R; Fietkau R; Gaipl US
    Strahlenther Onkol; 2016 Mar; 192(3):146-55. PubMed ID: 26646311
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Manganese superoxide dismutase (MnSOD) is a malignant astrocytoma specific biomarker and associated with adverse prognosis in p53 expressing glioblastoma.
    Shwetha SD; Shastry AH; Arivazhagan A; Santosh V
    Pathol Res Pract; 2016 Jan; 212(1):17-23. PubMed ID: 26616112
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Antiangiogenic therapy for glioblastoma: current status and future prospects.
    Batchelor TT; Reardon DA; de Groot JF; Wick W; Weller M
    Clin Cancer Res; 2014 Nov; 20(22):5612-9. PubMed ID: 25398844
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Prognostic impact of O6-methylguanine-DNA methyltransferase silencing in patients with recurrent glioblastoma multiforme who undergo surgery and carmustine wafer implantation: a prospective patient cohort.
    Metellus P; Coulibaly B; Nanni I; Fina F; Eudes N; Giorgi R; Barrie M; Chinot O; Fuentes S; Dufour H; Ouafik L; Figarella-Branger D
    Cancer; 2009 Oct; 115(20):4783-94. PubMed ID: 19637364
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Phase II study of ifosfamide, carboplatin, and etoposide in patients with a first recurrence of glioblastoma multiforme.
    Aoki T; Mizutani T; Nojima K; Takagi T; Okumura R; Yuba Y; Ueba T; Takahashi JA; Miyatake S; Nozaki K; Taki W; Matsutani M
    J Neurosurg; 2010 Jan; 112(1):50-6. PubMed ID: 19538050
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Response patterns of recurrent glioblastomas treated with tumor-treating fields.
    Vymazal J; Wong ET
    Semin Oncol; 2014 Oct; 41 Suppl 6():S14-24. PubMed ID: 25213870
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials.
    Wong ET; Hess KR; Gleason MJ; Jaeckle KA; Kyritsis AP; Prados MD; Levin VA; Yung WK
    J Clin Oncol; 1999 Aug; 17(8):2572-8. PubMed ID: 10561324
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Progression-free and overall survival in patients with recurrent Glioblastoma multiforme treated with last-line bevacizumab versus bevacizumab/lomustine.
    Heiland DH; Masalha W; Franco P; Machein MR; Weyerbrock A
    J Neurooncol; 2016 Feb; 126(3):567-75. PubMed ID: 26614518
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A novel treatment for glioblastoma: integrin inhibition.
    Chamberlain MC; Cloughsey T; Reardon DA; Wen PY
    Expert Rev Neurother; 2012 Apr; 12(4):421-35. PubMed ID: 22449214
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Targeting cancer stem-like cells in glioblastoma and colorectal cancer through metabolic pathways.
    Kahlert UD; Mooney SM; Natsumeda M; Steiger HJ; Maciaczyk J
    Int J Cancer; 2017 Jan; 140(1):10-22. PubMed ID: 27389307
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Phase II study of panobinostat in combination with bevacizumab for recurrent glioblastoma and anaplastic glioma.
    Lee EQ; Reardon DA; Schiff D; Drappatz J; Muzikansky A; Grimm SA; Norden AD; Nayak L; Beroukhim R; Rinne ML; Chi AS; Batchelor TT; Hempfling K; McCluskey C; Smith KH; Gaffey SC; Wrigley B; Ligon KL; Raizer JJ; Wen PY
    Neuro Oncol; 2015 Jun; 17(6):862-7. PubMed ID: 25572329
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Diffusion MRI Phenotypes Predict Overall Survival Benefit from Anti-VEGF Monotherapy in Recurrent Glioblastoma: Converging Evidence from Phase II Trials.
    Ellingson BM; Gerstner ER; Smits M; Huang RY; Colen R; Abrey LE; Aftab DT; Schwab GM; Hessel C; Harris RJ; Chakhoyan A; Gahrmann R; Pope WB; Leu K; Raymond C; Woodworth DC; de Groot J; Wen PY; Batchelor TT; van den Bent MJ; Cloughesy TF
    Clin Cancer Res; 2017 Oct; 23(19):5745-5756. PubMed ID: 28655794
    [No Abstract]   [Full Text] [Related]  

  • 53. Continuous tamoxifen and dose-dense temozolomide in recurrent glioblastoma.
    DI Cristofori A; Carrabba G; Lanfranchi G; Menghetti C; Rampini P; Caroli M
    Anticancer Res; 2013 Aug; 33(8):3383-9. PubMed ID: 23898108
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The role of octamer binding transcription factors in glioblastoma multiforme.
    Rooj AK; Bronisz A; Godlewski J
    Biochim Biophys Acta; 2016 Jun; 1859(6):805-11. PubMed ID: 26968235
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Extracellular vesicles in glioblastoma: Biomarkers and therapeutic tools.
    Cela I; Capone E; Trevisi G; Sala G
    Semin Cancer Biol; 2024 Jun; 101():25-43. PubMed ID: 38754752
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Glucocorticoids promote a glioma stem cell-like phenotype and resistance to chemotherapy in human glioblastoma primary cells: Biological and prognostic significance.
    Kostopoulou ON; Mohammad AA; Bartek J; Winter J; Jung M; Stragliotto G; Söderberg-Nauclér C; Landázuri N
    Int J Cancer; 2018 Mar; 142(6):1266-1276. PubMed ID: 29067692
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The prognostic value of MGMT promoter methylation in glioblastoma: A meta-analysis of clinical trials.
    Binabaj MM; Bahrami A; ShahidSales S; Joodi M; Joudi Mashhad M; Hassanian SM; Anvari K; Avan A
    J Cell Physiol; 2018 Jan; 233(1):378-386. PubMed ID: 28266716
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Glioblastoma targeted therapy: updated approaches from recent biological insights.
    Touat M; Idbaih A; Sanson M; Ligon KL
    Ann Oncol; 2017 Jul; 28(7):1457-1472. PubMed ID: 28863449
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Phase II study of bevacizumab and temsirolimus combination therapy for recurrent glioblastoma multiforme.
    Lassen U; Sorensen M; Gaziel TB; Hasselbalch B; Poulsen HS
    Anticancer Res; 2013 Apr; 33(4):1657-60. PubMed ID: 23564811
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study.
    Perry JR; Bélanger K; Mason WP; Fulton D; Kavan P; Easaw J; Shields C; Kirby S; Macdonald DR; Eisenstat DD; Thiessen B; Forsyth P; Pouliot JF
    J Clin Oncol; 2010 Apr; 28(12):2051-7. PubMed ID: 20308655
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.